

JOHN F. CROWLEY

Chairman of the Board, Chief Executive Officer

John F. Crowley is our Chairman and CEO. John's involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease—a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the Co-founder, President and CEO of Novazyme Pharmaceuticals, a biotech start-up conducting research on a new experimental treatment for Pompe disease (which he credits as ultimately



saving his children's lives). In 2001, Novazyme was acquired by Genzyme Corporation and John continued to play a lead role in the development of a drug for Pompe disease as Senior Vice President, Genzyme Therapeutics.

John and his family have been profiled on the front page of The Wall Street Journal and are the subjects of a book by Pulitzer prize-winning journalist Geeta Anand, "The Cure: How a Father Raised \$100 Million-And Bucked the Medical Establishment-In a Quest to Save His Children." The major motion picture, *Extraordinary Measures*, starring Brendan Fraser and Harrison Ford, is inspired by the Crowley family journey. John is the author of a personal memoir: *Chasing Miracles: The Crowley Family Journey of Strength, Hope, and Joy*.

John is also a commissioned officer in the U.S. Navy Reserve, assigned to the United States Special Operations Command and is a veteran of the global war on terrorism, with service in Afghanistan. He graduated with a B.S. in Foreign Service from Georgetown University, and earned a J.D. from the University of Notre Dame Law School and an M.B.A. from Harvard. The Crowley family was the recipient of the 2011 Family Exemplar Award from the University of Notre Dame. He is also a member of the University Council on Science & Technology at Notre Dame. He is the National Chairman of the Make A Wish Foundation of America and is a founding Board member of the Global Genes Project. John is a Henry Crown Fellow at the Aspen Institute.

BRADLEY L. CAMPBELL

President and Chief Operating Officer

Bradley L. Campbell is the President and Chief Operating Officer of Amicus and brings over 15 years of experience in the Orphan Drug industry. After joining in 2006, he subsequently took on roles of increasing responsibility throughout the organization. In his current capacity, Mr. Campbell leads the strategy, design and leadership of global commercial operations to support the launch of migalastat, a small molecule personalized medicine in development for the treatment of Fabry Disease. He also oversees Technical Operations, Global Marketing, and Program Management functions.

Prior to Amicus, Mr. Campbell was with Genzyme, serving first as Product Manager for Myozyme® for Pompe disease and later as Business Director of their cardiac gene therapy programs. He has also worked in sales and marketing for Bristol-Myers Squibb, and as a strategy consultant for Marakon Associates.

Mr. Campbell is active with various Boards and philanthropic organizations. He serves as a member of the Board of Directors of Progenics Pharmaceuticals, a public company developing innovative medicines and other products for targeting and treating cancer. He is a member of the BioNJ Board of Directors and is Amicus' representative to HINJ (Health Care Initiative of New Jersey) Board of Trustees. He is a past President of the National Tay-Sachs and Allied Diseases Association Board of Directors, and currently serves on their Corporate Advisory Council. Bradley received a B.A. in Public Policy from Duke University and an M.B.A. from Harvard Business School.



DIPAL DOSHI

Chief Business Officer of Amicus Therapeutics, Inc. and General Manager of Scioderm, Inc.

Dipal Doshi joined Amicus in July 2014 and currently serves as Chief Business Officer of Amicus and General Manager of Scioderm, Inc., an Amicus Company. Prior to joining Amicus, Mr. Doshi founded RStreet Advisors, a healthcare consulting firm through which he advised pharmaceutical, biotech and diagnostics companies on business development, corporate strategy, market and commercial planning



activities. From 2008 to 2013, Mr. Doshi was the Senior Vice President and member of the management team at Auvon Therapeutics, a 200MM+ global private equity and bio-pharmaceutical development company. Mr. Doshi led or participated in the operations and financing of several biotech and pharmaceutical companies and held Board Observer positions for both Spirogen (acquired by AstraZeneca) and ADC Therapeutics.

From 2005 to 2008, Mr. Doshi was the Head of Corporate Development for Catalent Pharma Solutions (CTLT). Prior to Catalent, Mr. Doshi was a member of Merrill Lynch's Investment Banking Group. During his tenure at Eli Lilly, Mr. Doshi was a member of both the Strategic Marketing team and Lilly Ventures where he developed and led a portfolio company. He was also a sales representative in New York. As a consultant for both Mercer Management Consulting (Oliver Wyman) and Sapient Corporation (Publicis), Mr. Doshi advised healthcare, consumer and technology companies.

Mr. Doshi received a B.A. from Rutgers University and an M.B.A. from The Wharton School of the University of Pennsylvania.

HUNG DO PH.D.

Chief Science Officer

Hung Do joined Amicus in December 2013 and currently serves as Chief Scientific Officer. Dr. Do brings experience in the field of lysosomal storage diseases (LSDs) and enzyme replacement therapies (ERTs). Prior to joining Amicus, Dr. Do was a Co-founder and Chief Scientific Officer of Callidus Biopharma, a



privately-held biologics company that was acquired by Amicus. Prior to founding Callidus, he headed early discovery research to decipher the mechanism of action for small molecule pharmacological chaperones at Amicus. He previously helped to demonstrate proof-of-concept for ERTs, and served as the project leader for a second-generation Pompe ERT at Genzyme. Dr. Do also led molecular biology, cell culture and purification work and helped develop an in vitro protein modification process for improving drug targeting for protein therapeutics at Novazyme, which was acquired by Genzyme.

Dr. Do holds a Ph.D. in medical biochemistry and genetics from Texas A&M University (mentored by Professor Arthur E. Johnson) and was a post-doctoral fellow in Hematology/Oncology at Emory University (Dr. John S. Lollar). Dr. Do utilizes his focused training in protein synthesis, folding & trafficking to develop better targeted therapeutic treatments for genetic diseases.

JAY A. BARTH M.D.

Chief Medical Officer

Jay A. Barth joined Amicus Therapeutics in March 2014 as Chief Medical Officer. Dr. Barth brings experience in drug development, clinical research and medical affairs. Prior joining Amicus, Dr. Barth held roles of increasing responsibility at PTC Therapeutics, Inc. from 2009 to 2014. He most recently served as PTC's Senior Vice President, Clinical Development. In this role he led the clinical team and oversaw all global clinical development programs, focusing on rare diseases including Duchenne Muscular Dystrophy and Cystic Fibrosis. Previously Dr. Barth served as Executive Director of Clinical Research at Merck; as Vice President, Clinical Research and Medical Affairs at Altana Pharma US, Inc; and as Senior Director, Global Head of Gastroenterology Clinical Research at Eisai Medical Research Inc.



Dr. Barth received a B.A. from Columbia University and an M.D. from the University of Pennsylvania School of Medicine. He is a member of the American Gastroenterological Association, the American College of Gastroenterology, and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. He is also the author of numerous publications in the fields of medicine and clinical research.

JAYNE C. GERSHKOWITZ

Chief Patient Advocate

Jayne C. Gershkowitz joined Amicus in June 2006 and currently serves as Chief Patient Advocate. She is a long-time patient advocacy professional with expertise in the rare disease community, specifically in



the LSD space. Prior to joining Amicus, Ms. Gershkowitz served as Executive Director at the NTSAD Association, where she co-founded the LSD Research Consortium in partnership with the National Institute of Neurological Disorders and Stroke (NINDS) and established the NTSAD Research Initiative. Her earlier career experience encompasses newspaper journalism; corporate and non-profit marketing communications; and social services.

Ms. Gershkowitz is active in several organizations within the rare disease community as well as the broader biotech arena. She is a Co-founder and Chair of the Patient Advocacy Committee of BioNJ, and Vice President of Education of the Board of Directors of the NTSAD Association. She is currently a member of the Steering Committee of the Healthcare Institute of New Jersey; the Patient Advocacy and Access and Reimbursement Committees of the Corporate Alliance of the Global Genes RARE Project; and the Policy Working Group of the National Organization for Rare Disorders Corporate Council. Ms. Gershkowitz earned a degree in journalism from the the Newhouse School of Public Communications at Syracuse University and studied business administration at the Radcliffe Graduate Seminars Program.

WILLIAM D. "CHIP" BAIRD, III

Chief Financial Officer

William D. "Chip" Baird joined Amicus Therapeutics in April 2012 as Chief Financial Officer. He brings experience in finance and strategic planning. Prior to Amicus Mr. Baird held roles of increasing responsibility for over 10 years at PTC Therapeutics, Inc. As Chief Financial Officer of PTC from April 2005 to April 2012, he was responsible for all areas of finance, investor and public relations, human resources, facilities and project management. During his tenure at PTC, he was instrumental in raising over \$500 million through a combination of venture capital, non-dilutive grant funding, collaborations with industry-leading pharmaceutical and biotech companies, and debt financings. Previously, Mr. Baird worked at L.E.K. Consulting, a strategy consulting firm, from 1999 to 2002 and at First Union National Bank as a corporate underwriter from 1994 to 1997.



Mr. Baird received a B.S. from Georgetown University's Edmund A. Walsh School of Foreign Service and an M.B.A. in finance from The Wharton School of the University of Pennsylvania.